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CTLA-4 Ligation Blocks CD28-dependent  T Cell Activation 
By Theresa L.Walunas, Christina Y. B akker, and Jeffrey A. Bluestone 
From the Committee on Immunology, Department ofPathology and the Ben May Institute for Cancer 
Research, The University of Chicago, Chicago, illinois 60637 
Summary 
CTLA-4 is a CD28 homologue beheved to be a negative regulator of T cell function. How- 
ever, the mechanism of this downregulatory activity is not well understood. The present study 
was designed to examine the effect of CTLA-4 ligation on cytokine production, cell survival, and 
cell cycle progression. The results demonstrate hat the primary effect of CTLA-4 ligation is 
not the induction ofapoptosis. Instead, CTLA-4 signaling blocks IL-2 production, IL-2 receptor 
expression, and cell cycle progression of activated T cells. Moreover, the effect of CTLA-4 sig- 
naling was manifested after initial T cell activation. Inhibition oflL-2 receptor expression and cell 
cycle progression was more pronounced at late (72 h) time points after initial activation. The 
effects of anti-CTLA-4 mAbs were most apparent in the presence of optimal CD28-medi- 
ated costimulation consistent with the finding that CTLA-4 upregulation was CD28-depen- 
dent. Finally, the addition of exogenous IL-2 to the cultures restored IL-2 receptor expression 
and T cell prohferation. These results uggest that CTLA-4 signaling does not regulate cell sur- 
vival or responsiveness to IL-2, but does inhibit CD28-dependent IL-2 production. 
C D28/B7 interactions play a central role in providing costimulatory signals to T cells. Ligation of CD28 by 
B7-1 and/or B7-2 has been shown to induce T cells to 
regulate growth factor (IL-2) production (1, 2), T helper 
cell differentiation (3, 4), and programmed cell death (5). 
Over 8 yr ago, a structural homologue of CD28, CTLA-4, 
was discovered among a set of T cell-specific, activation- 
induced genes (6). Not only was CTLA-4 found to share 
structural homology with CD28, but it also shares the abil- 
ity to bind B7-1 and B7-2 (7, 8). Further studies demon- 
strated that the CTLA-4 glycoprotein is expressed on the 
surface of activated CD4 + and CD8 + T cells (9-11) and on 
activated B cells (12). Whereas CD28 is constitutively ex- 
pressed on resting human and murine T cells (13), CTLA-4 
is upregulated after T cell activation, with peak expression 
between 48-72 h (9, 10). Initial studies have also suggested 
that CTLA-4 upregulation is CD28-dependent. First, anti- 
CD28 mAbs accelerate he kinetics ofCTLA-4 mRNA ac- 
cumulation in human PBL (14). Second, the degree of 
CTLA-4 upregulation was significantly reduced on T cells 
from CD28-deficient mice (10). 
Early findings suggested that CTLA-4 hgation on acti- 
vated T cells provided additional costimulatory signals (9). 
However, recent studies in vitro (10, 11) and in vivo (15) 
have suggested that rather than acting to costimulate T cells, 
CTLA-4 may actually be involved in the downregulation 
of T cell responses, perhaps as an antagonist of CD28 co- 
stimulation. Monovalent Fab fragments of an anti-murine 
CTLA-4 mAb, which prevent he interaction of CTLA-4 
with its counter-receptors, augment prohferation of purl- 
fled T cells by interrupting the transduction of a negative 
signal (10). In contrast, whole anti-CTLA-4 mAbs, that 
could cross-link CTLA-4, inhibited T cell proliferation when 
the T cells were activated by anti-CD3 in the presence of 
optimal CD28 costimulation. Monovalent Fab fragments 
of the antibody, that cannot cross-link CTLA-4, had no ef- 
fect in this system (t0). In addition to the in vitro and in 
vivo data using mAbs, there is now direct evidence for a 
physiologic role for CTLA-4 in the downregulation facti- 
vated T cells. CTLA-4-deficient mice manifest a massive lym- 
phoproliferative disorder, increased numbers of activated T 
cells and autoimmune-like tissue destruction (16, 17). These 
data are consistent with an integral role for CTLA-4 signal- 
ing in the negative regulation of activated T cells. 
Although there is now ample evidence to suggest hat 
CTLA-4 is involved in the downregulation of activated T 
cells, the mechanism remains unclear. Two possibilities eem 
plausible. First, CTLA-4 hgation may inhibit T cell function 
by inducing apoptosis in activated T cells. In support of this 
possibility, Gribben et al. (18) have shown that incubation 
of preactivated human T cells with antigen in the presence 
of an anti-CTLA-4 mAb induces apoptosis. Second, CTLA-4 
may inhibit T cell activation by preventing early or late 
events in T cell activation,, such as gene expression, growth 
factor production, and/or cell cycle progression. If CTLA-4 
is a CD28 antagonist, it is possible that it may function, in 
particular, to regulate IL-2 production, a growth factor 
known to be induced by CD28 hgation and to be impor- 
tant for cell cycle progression and T cell expansion. 
In the present study, anti-CTLA-4 mAb were used to 
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further examine the role of CD28 in the regulation of 
CTLA-4 expression as well as the mechanism by which 
CTLA-4 inhibits T cell activation. The results demonstrate 
that CTLA-4 expression on naive T cells is regulated by 
costimulation through CD28/B7-2 interactions. In addi- 
tion, antibodies to CTLA-4 inhibit ant i -CD3/ant i -CD28- 
induced T cell proliferative responses by blocking IL-2 
production, sustained IL-2 receptor expression and events 
that regulate progression of the cells into the cell cycle. 
CTLA-4 does not seem to regulate programmed cell death. 
Materials and Methods 
Animals. 4--8-wk-old C57BL/6 (B6) mice were purchased from 
Frederick National Cancer Institute (Bethesda, MD). 4--8-wk-old 
2C TCR transgenic (2C) 1 mice were derived as previously de- 
scribed (19), bred, and maintained under specific-pathogen free 
conditions in the University of Chicago Animal Barrier Facility. 
2C • Ipr/Ipr [2C(lpr)] mice were generated by breeding 2C ani- 
mals to B6.1pr/Ipr (purchased from the Jackson Laboratory, Bar 
Harbor, ME). F1 mice were screened for the 2C transgenes with 
the anti-clonotypic mAb, 1B2 (20) and 2C Tg + F1 mice were 
bred back to B6.1pr/lpr. Offspring of this mating were screened 
for the 2C transgenes a described above and for the Ipr mutation 
by polymerase chain reaction (PCR) of tail DNA as described 
elsewhere (21). 2C(Ipr) mice were used at 3-5 wk of age. 
Cell Lines and Reagents. UC10-4F10-11 (hamster anti-murine 
CTLA-4 [10]), 145-2Cll (hamster anti-murine CD3 [22]), 2.4G2 
(rat anti-mouse FcR [23]), 1B2 (mouse anti-2C TCR [20]), J11d 
(rat anti-murine HSA [24]), GL-1 (rat anti-murine B7-2 [25]), 
AT83A (rat anti-Thyl.2 [26]), and the 25-9-3 (mouse anti-I-A b
[27]) were prepared in our laboratory. PV-1 (hamster anti-murine 
CD28 [28]) was kindly provided by Dr. Carl June (Naval Medical 
Research Institute, Bethesda, MD). Purified hamster Ig (purchased 
from Cappel Research Products, Durham, NC) was used as neg- 
ative control hamster antibodies in in vitro cultures. Control hu- 
man Ig, human CTLA4Ig, 16-10A1 (hamster anti-murine B7-1 
[29]) and Fab fragments of the anti-CD28 n~Ab were provided by 
the Repligeu Corporation (Cambridge, MA). The coding se- 
quence for the extracellular portion of human CTLA-4 was 
joined to the hinge-CH2-CH3 domains derived from a human 
genomic IgG1 gene by PCR as previously described (30). Fab 
fragments of the anti-CTLA-4 mAb, UC10-4F10-11 were gen- 
erated in our laboratory as previously described (10). Anti- 
CTLA-4 Fab fragments were tested in comparison towhole anti- 
CTLA-4 mAb for their ability to competitively inhibit binding of 
FITC-conjugated UC10-4F10-11 to CTLA-4 transfected CHO 
cells (10). The Fab fragments inhibited binding of the FITC-conju- 
gated anti-CTLA-4 "~10-fold less well than whole anti-CTLA-4. 
However, multiple studies both in vitro (10) and in vivo (15) 
have shown that the doses of Fab used in the present studies are 
sufficient to mediate biological effects. Rat anti-murine CD8 
(2.43 [31]) and hamster anti-murine CTLA-4 (UC10-4F10-11 
[10]) coupled to FITC were prepared in our laboratory. Biotiny- 
lated anti-IL-2R (7D4) was purchased from PharMingen (San 
Diego, CA). HTC-conjugated anti-CD3 (145-2Cll)was pro- 
vided by Boehringer Mannheim (Indianapolis, IN). Phycoeryth- 
1Abbreviations u ed in this paper: 2C, 2C TCR transgenic; t36, C5713L/6; 
control Ig, control hamster immunoglobulin; FcR, Fc receptor; PCD, 
programmed cell death; Tg, transgenic; TUNEL, terminal deoxynucleo- 
tidyl transferase dUTP nick end labeling. 
fin-conjugated streptavidin (SAV-PE) was purchased from South- 
ern Biotech (Birmingham, AL). 
Bulk T Cell Activation Cultures to Examine CTLA-4 Induction. 
Spleens were harvested from B6 mice and depleted of erythro- 
cytes with ammonium chloride-potassium lysing buffer. Spleno- 
cytes were cultured alone in DMEM containing 10% fetal calf 
serum or in the presence of 10 lag/ml soluble anti-CD3. To ex- 
amine the role of CD28 in the regulation of CTLA-4 expression, 
Fab fragments of anti-CD28, CTLA~Ig, anti-B7-1, anti-B7-2, 
control human Ig or control hamster Ig were added at 100 I~g/ml 
final concentration. Cells were examined for CTLA-4 expression 
by flow cytometry at 48 h after the initiation of culture. 
Flow Cytometric Analysis. After harvest, cells were washed once 
in FACS | buffer (0.1% BSA and 0.01% Sodium Azide in PBS, 
pH 7.4) and simultaneously tained with FITC- and biotin-con- 
jugated mAb as described for 30 rain at 4~ Cells were washed 
again in FACS | buffer and incubated with SAV-PE to develop 
biotinylated mAb for 15 rain at RT. After a final wash in FACS | 
buffer, cells were analyzed on a FACScan | flow cytometer (Bec- 
ton-Dickinson, Mountain View, CA). Incorporation of propid- 
ium iodide was used to exclude dead cells. Data was analyzed us- 
ing both Lysis II (Becton-Dickinson) and WinMDI software 
(Joseph Trotter, Salk Institute, available by anonymous ftp offflo- 
sun.salk.edu in/pub/pc). 
T Cell Proliferation Assays. 2C and 2C(lpr) lymph node cells were 
enriched for T cells by passage over nylon wool columns. MHC 
Class I1 + cells were further depleted using a mixture ofanti-HSA 
(Jlld) and anti-I-A b(25-9-3) culture supernatants plus rabbit com- 
plement (Pel-Freez, Brown Deer, WI). T cell purity was evalu- 
ated by flow cytometry using anti-CD3 mAb. In all cases, T cells 
used in these assays were >97% CD3 +. Purified T cells were 
plated out at 2 X 10S/well in the presence of I • 105 irradiated 
(2,000 rads) syngeneic, erythrocyte-depleted B6 splenocytes. Syn- 
geneic feeder cells were depleted of T cells by incubation with 
anti-Thy 1.2 and rabbit complement. Anti-CD3 (0.1 Ixg/ml), anti- 
CD28 (1 p~g/ml), anti-CTLA-4 (50 Ixg/ml), control hamster IgG 
(50 p~g/ml), anti-CTLA-4 Fab fragments (50 p,g/nil), and recom- 
binant human 1L-2 (rlL-2) (50 U/nil) were used as described in 
the results ection. Assays were carried out for 72 h at 37~ and 
were pulsed with 1 IxCi/well [3H]thymidine (Amersham Corp., 
Arlington Heights, IL) for the last 16 h of culture. Counts are 
represented asthe mean of triplicate wells with standard errors 
<10%. All experiments were carried out a minimum of three 
times with similar esults. 
IL-2 Determination. Superuatants from duplicate cultures of the 
above described proliferation assays were harvested at 24 h after 
initiation of culture and stored at -20~ until assayed using a 
commercial IL-2 ELISA kit from Endogen (Cambridge, MA). A 
murine IL-2 standard was used to quantify IL-2 levels in the su- 
pernatants (represented aspg/ml). 
Terminal Deoxynucleotidyl Transferase (Tdt)-mediated dUTP Nick 
End Labeling (TUNEL) Assay for Apoptosis. Cells were harvested 
72 h after the initiation of culture and washed once in FACS | 
buffer. Harvested cells were fixed overnight at 4~ in 1% para- 
formaldehyde. Cells were then washed twice in PBS before incu- 
bation in Tdt buffer containing 2.5 mM CoC12 (as supplied by 
Boehringer Mannheim (Indianapolis, IN). DNA degradation was 
determined by the level of incorporation fBODIPY-conjugated 
dUTP (Molecular Probes, Eugene, OR) when Tdt enzyme was 
added to the fixed cells. Suspended cells were incubated in the 
dark for 30 rain in a 37~ water bath, with or without Tdt, washed 
once in 15 mM EDTA, once in 0.1% Triton-X 100, and finally 
suspended in PBS. Cells were analyzed for BODIPY-dUTP in- 
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corporafon by flow cytometry. Logarithmically amplified fluo- 
rescence data were collected on 5 • 103 cells. 
Cell Cycle Analysis. Cultured cells were passed over Ficoll- 
Hypaque to remove dead cells. The live cells were stained with 
anti-CD8-FITC in FACS | buffer, washed in PBS and fixed in 
0.25% paraformaldehyde for 15 min at room temperature. Cells 
were washed once in PBS, fixed with 70% methanol and stored 
overnight at -20~ After 2 washes in PBS, cells were treated 
with IkNase at 10 p~g/ml at 37~ for 30 min. Cells were washed 
once in PBS and resuspended in PBS containing 10 ~g/ml pro- 
pidium iodide. Logarithmically amplified fluorescence data was 
collected on 104 cells. 
Results 
Anti-CTLA-4 mAb Ig But Not Fab Fragments Inhibit T Cell 
Proliferative Responses. As described previously (10), anti- 
CTLA-4 mAb, when cultured in the presence of anti-CD3 
mAb and optimal costimulation via an anti-CD28 mAb, in- 
hibited T cell proliferation. This inhibition of  proliferation 
required Fclk cross-linking of  the anti-CTLA-4 mAb be- 
cause Fab fragments of  the anti-CTLA-4 mAb had no effect 
on proliferation in this system (Fig. 1 A). The Fab fragments 
have previously been shown to effectively bind CTLA-4 and 
modulate immune responses both in vitro (10) and in vivo 
(15). Similar results were observed upon stimulation of  2C 
TC1K Tg lymph node cells with alloantigen or the bacterial 
superantigen staphylococcal enterotoxin B (data not shown). 
It is unlikely that the anti-CTLA-4 mAb blocked prolifera- 
tion by competing for Fclk-mediated cross-linking of  the 
anti-CD3 or anti-CD28 mAbs since the anfi-CTLA-4 mAb 
did not inhibit anti-CD3-mediated T cell activation (Fig. 1 
B). In fact, in multiple experiments (Fig. 1 B and reference 
10), anti-CTLA-4 mAbs siguificantly enhance proliferative 
responses in the absence of maximal CD28 costimulation. 
Finally, these results have been confirmed and extended by 
studies of  other investigators using anti-CTLA-4 mAbs di- 
rectly immobilized on plastic beads with anti-CD3 and 
anti-CD28 mAbs (11). 
CD28 Signaling Regulates CTLA-4 Upregulation. Optimal 
CD28 costimulation was essential for the anti-CTLA-4 mAbs 
to manifest heir inhibitory activity. These results suggested 
that CTLA-4 expression and/or signaling was dependent 
on CD28 engagement. Previous studies using CD28-defi- 
cient mice have suggested that CD28 costimulation was es- 
sential for maximal upregulation of  CTLA-4 expression 
(10). To directly examine the role of  CD28/B7 interac- 
tions in CTLA-4 upregulation, whole B6 spleen cells were 
stimulated with anti-CD3 in the presence of anti-CD28 
Fab fragments or CTLA4Ig. As seen in Fig. 2 (A) both 
CD28 antagonists inhibited the upregulation of  CTLA-4 
on the CD8 + T cells. Interestingly, the addition of  anti- 
B7-2, not anti-B7-1, inhibited CTLA-4 expression (Fig. 2/3) 
consistent with previous findings suggesting a primary role 
of  B7-2 in CD28-mediated T cell costimulation. Thus, op- 
timal CTLA-4 expression is dependent on costimulation of  
T cells through the CD28 receptor. In fact, the require- 
ment for CD28 signals to upregulate CTLA-4 expression after 
T cell activation may explain, in part, why the inhibitory 
effects of  the anti-CTLA-4 mAb are only observed in the 
presence of optimal costimulation through CD28 (Fig. 1 B). 
The enhanced proliferative response observed in the ab- 
sence of  anti-CD28 costimulation may reflect an ability of  
even small levels of  high affinity CTLA-4 to compete for 
B7 binding by CD28. 
Inhibition of Proliferation by Anti-CTLA-4 in the Presence of 
Anti-CD28 Is Not Fas-dependent. Previous tudies using hu- 
man T cells have suggested that the engagement of CTLA-4 
inhibits T cell proliferation by inducing apoptosis of  the ac- 
tivated T cells (18). Fas-mediated cell death has been pro- 
posed to be a major pathway for regulating cell expansion 
after TC1K ligation in several model systems (32). There- 
fore, the role of  Fas in anti-CTLA-4-mediated suppression 
of  proliferation was directly examined using the Fas-defi- 
cient Ipr mouse (33, 34). 2C mice ~vere bred to B6.1pr/Ipr 
[2C(Ipr)]. Tg § T cells from these animals, which produce a 
defective Fas protein that is unable to transduce an apop- 
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Figure 1. Anti-CTLA-4 inhi- 
bition of 2C T cell proliferation 
is CD28-dependent. Two-hun- 
dred thousand purified 2C TCR, 
Tg + T cells were cukured with 
1 X 105 syngeneic, irradiated 
T-depleted splenocytes in the 
presence of both suboptimal 
TCR stimulation (0.1 p,g/ml 
anti-CD3) and optimal co-stim- 
ulation (1.0 Ixg/ml anti-CD28) 
(A) or in the presence of anti- 
CD3 stimulation alone (B). Con- 
trol Ig, anti-CTLA-4 or anti- 
CTLA-4 Fab fragments were 
added at 50 ~g/ml. The assay 
was harvested at 72 h after a 16-h 
pulse with 1 ~Ci/well [3H]thy- 
midine. 
Figure 2. Co-stimulation through CD28 regulates CTLA-4 expres- 
sion. CTLA-4 upregulation was examined in the presence of Fab frag- 
ments of anti-CD28 mAb, CTLA4Ig, anti-B7-1 or anti-BT-2 mAb. B6 
splenocytes were cultured in the presence ofanti-CD3 and 100 ~g/ml of 
the indicated antagonist r control Ig for 48 h. CTLA-4 expression was 
examined on the CD8 + T cells by two-color flow cytometry. Data repre- 
sents the mean fluorescence intensity of anti-CTLA-4 staining on the 
CD8 + T cell population. 
totic signal, were analyzed for their ability to proliferate in re- 
sponse to anti-CD3 and anti-CD28 in the presence/absence 
of anti-CTLA-4 mAbs. The presence of  anti-CTLA-4 
mAbs in the activation cultures resulted in profound inhi- 
bition of  anti -CD3/anti -CD28-induced T cell prolifera- 
tion (Fig. 3) similar to that observed with control Fas + 2C 
T cells (Fig. 1 A). Together, these results suggested that the 
mechanism of  CTLA-4-mediated effects on T cell prolifer- 
ation was not via a Fas-dependent apoptotic pathway. 
Inhibition of T Cell Proliferation by Anti-CTLA-4 mAbs Is 
Not Mediated by Apoptosis. Recent studies have supported 
Fas-independent mechanisms ofapoptosis after TC1K ligation 
(35). Thus, a TUNEL  assay was used to examine whether 
the anti-CTLA-4 mAbs induced DNA degradation consis- 
tent with Fas-independent programmed cell death. As pre- 
viously shown (5, 10) T cells stimulated with anti-CD3 in 
the absence of  CD28 costimulation exhibit significantly re- 
duced proliferative responses and profound apoptotic death. 
As seen in Fig. 4, 2C Tg + T cells proliferated poorly to 
anti-CD3 alone (A) and over 40% of the cells were ob- 
served to be undergoing apoptosis at 72 h (B). The addition 
of anti-CD28 mAb significantly increased proliferation and 
reduced the percentage of  cells undergoing apoptosis (6.1- 
9.5%) (Fig. 4 B). These results are consistent with previous 
studies demonstrating the cell survival effects of  CD28 sig- 
naling (5). The effects of anti -CTLA-4 mAbs were exam- 
ined in this assay. Although the proliferation of activated T
cells was significantly inhibited by the addition of  the anti- 
CTLA-4 mAbs (Fig. 4 A), the percentage ofapoptotic ells 
remained comparable to the level observed in control cul- 
tures (Fig. 4 B). These data suggested that downregulation 
of proliferation by CTLA-4 cross-linking was not mediated 
by induction of  apoptosis in activated T cells. Moreover, 
the results support previous evidence that the anti-CTLA-4 
mAb does not mediate its suppressive ffects by competing 
with anti-CD28 for FclK engagement since blockade of CD28 
signaling would have been expected to promote apoptosis. 
Figure 3. Anti-CTLA-4-mediated inhibition of proliferation is Fas- 
independent. 2C T cell proliferation assays were set up as described in Fig. 1. 
Responding T cells were purified from the lymph nodes of 2C (Ipr) mice. 
The results depicted in this figure are representative of three separate ex- 
periments. 
CTLA-4 Suppresses Late, but Not Early, Cell Cyde Progres- 
sion. The previous results suggested that CTLA-4 regulates 
T cell proliferation by inhibiting proliferation independently 
of  programmed cell death (PCD), perhaps by blocking T 
cells from progressing through the cell cycle. To address 
this issue directly, we examined the ability of ant i -CD3/ 
anti-CD28-activated T cells to progress through the cell 
cycle in the presence of  anti -CTLA-4 mAbs. As seen in 
Fig. 5, there was no apparent difference in the progression 
o fT  cells into the cell cycle at he early (24 h) time point in 
anti-CD3/anti-CD28-stimulated T cells cultured in the 
absence or presence of  the anti-CTLA-4 mAbs. In contrast, 
there were consistently less T cells (15%) in the S /G2-M 
phase of the cell cycle in the anti-CTLA-4-treated cultures 
when compared to control Ig-treated cultures at 72 h. As 
previously noted, CTLA-4 is upregulated after initial T cell 
activation. Therefore, it is likely that he inhibitory effect 
of CTLA-4 ligation is subsequent to the initiating signals 
after TCIK ligation that are responsible for driving T cells 
into early phases of  the cell cycle. 
Signals through CTLA-4 Inhibit Sustained Expression of IL-2 
Receptor (IL-2Ra) and IL-2 Production. The previous results 
suggested that CTLA-4 acts subsequently to the initial TCR 
signaling events to regulate T cell growth. Therefore, we 
examined two events known to be important for sustained 
T cell growth, the expression of  the low affinity IL-2Ro~ 
chain and production of IL-2. Fig. 6 shows the kinetics of 
IL-2Rcx chain expression on 2C TCR Tg + T cells acti- 
vated under control conditions or in the presence of  anti- 
CTLA-4 mAbs. Although there was no observable ffect of 
the anti-CTLA-4 mAb on the level of  IL-2Ro~ chain ex- 
pression on the surface of the activated T cells at 24 h, a 
marked decrease in IL-21Kcx expression was evident by 48 h 
(data not shown) and 72 h (Fig. 6). Thus, low affamty IL-2Rcx 
chain expression on activated T cells is inhibited by signal- 
ing via CTLA-4. 
The anti-CTLA-4 mAbs appeared to have a preferential 
effect on late events in cell cycle progression and IL-2Re~ 
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Figure 4. Inhibition of prolif- 
eration by anti-CTLA-4 mAb is 
not mediated by apoptosis. The 
proliferation assay was set up as de- 
scribed in Fig. 1. A depicts the 
proliferative response of 2C T 
cells subjected to the PCD analy- 
ses. B depicts he PCD analysis. 
2C cells were harvested at 72 h 
after the initiation of culture. 
Apoptosis was measured as e- 
scribed in Materials and Methods 
using the TUNEL assay. The 
amount of apoptosis was deter- 
mined by examining the number of cells that incorporated the fluorescein-conjugated dUTP (BODIPY-dUTP) in each sample byflow cytometry. This 
assay is representative of three separate experiments. 
expression. Previous studies have shown that IL-2 is a posi- 
tive regulator o f  IL-2P,.c~ expression (36) and is essential for 
cell cycling, though less is known about the regulation o f  
functional high affinity IL -2R.  Therefore IL-2 product ion 
by Tg  § T cells stimulated with ant i -CD3/ant i -CD28 in 
the presence o f  a control  hamster IgG or ant i -CTLA-4  
mAb was examined. Significant suppression f  IL-2 pro-  
duct ion (70% in the exper iment shown in Fig. 7) by the 
addit ion o f  ant i -CTLA-4  mAbs was observed in repeated 
experiments, consistent with a direct role for CTLA-4  in 
the regulation o f  IL-2. In fact, the addit ion o f  exogenous 
IL-2 promoted the aborted cell cycle progression (Fig. 5), 
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Figure 5. CTLA-4 ligation inhibits cell cycle 
progression. Purified 2C T cells were activated as 
previously described and harvested at either 24 or 
72 h. Cells were stained with CD8-FITC, fixed 
and DNA staining was performed as described in 
Materials and Methods. The DNA distribution of 
CD8 + T cells is depicted by histograms. The per- 
centage of cells in S/G 2 was determined by com- 
parison of activated cell populations with an un- 
stimulated control 2C T cell population. The top 
left and right panels represent cells stimulated with 
anti-CD3/anti-CD28 in the presence of control Ig. 
The middle left and right panels represent cells 
stimulated with anti-CD3/anti-CD28 in the pres- 
ence of anti-CTLA-4 mAbs. The bottom left and 
right panels represent cells stimulated with anti- 
CD3/anti-CD28 and anti-CTLA-4 mAb in the 
presence of exogenous human recombinant IL-2 (50 
U/ml). 
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Figure 6. Sustained IL-2 receptor expression is in- 
hibited by anti-CTLA-4 mAb. Purified 2C T cells 
were stimulated as previously described in Fig. 1 
with anti-CD3 and anti-CD28 in the presence of 
control hamster Ig (top), anti-CTLA-4 (middle), or 
anti-CTLA-4 plus IL-2 (bottom). The 2C T cells 
were harvested at 24 and 72 h after activation and 
examined for IL-2R expression by two-color flow 
cytometry. The data is represented as histograms for 
IL-2R expression after gating on CD8 + T cells. 
reversed the downregutat ion o f  IL-2Rcx expression (Fig. 6) 
and reconstituted T cell prol iferation (Fig. 8) in the anti- 
CTLA-4  treated cultures. Together  these data suggest hat 
CTLA-4  acts to suppress IL-2 product ion,  resulting in de- 
creased IL-2P,.0t expression, but not IL-2 responsiveness, 
under culture condit ions where there is optimal costimula- 
tion through CD28.  
Figure 7. CTLA-4 ligation in the presence of CD28 costimulation i - 
hibits the production oflL-2. Purified 2C T cells were stimulated with anti- 
CD3 (0.1 ~g/ml) or anti-CD3 and anti-CD28 (1 ~g/ml) in the presence 
of Control Ig, anti-CTLA-4, or anti-CTLA-4 Fab fragments (50 Ixg/ml) 
in the presence ofT cell depleted, syngeneic irradiated feeder cells. Super- 
natants were collected at 24 h and tested for the presence of IL-2 by 
ELISA. 
Discuss ion  
The funct ion o f  CTLA-4 ,  a cell surface molecule on ac- 
tivated T cells (originally identif ied in a mRNA library o f  
activated CTL), remains controversial. CTLA-4  was shown to 
bind B7-1 /B7-2  and, based on its sequence homology  to 
the CD28 molecule,  was predicted to funct ion as a mem-  
ber o f  the CD28 class o f  costimulatory molecules. In fact, 
early studies supported a costimulatory role for CTLA-4  in 
promot ing  T cell proliferation (9, 37). However ,  more re- 
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Figure 8. Inhibition of proliferation by anti-CTLA-4 mAb can be re- 
versed by the addition of exogenous IL-2. Purified 2C T cells were stim- 
ulated with anti-CD3 and anti-CD28 (as described inFig. 1) in the pres- 
ence of Control Ig, anti-CTLA-4 mAb or anti-CTLA-4 mAb and 
recombinant human 1L-2 (50 U/ml) (Anti-CTLA-4/IL-2). Proliferation 
was measured at both 24 and 72 h after the initiation of culture. 
cent studies have suggested that rather than promoting T
cell activation, engagement of CTLA-4 actually inhibits T cell 
function (10, 11, 18). First, we showed that blockade of 
CTLA-4 engagement with its natural igands by Fab frag- 
ments of anti-CTLA-4 mAbs enhanced T cell proliferation 
both in vitro and in vivo (10, 15). In addition, we, and 
others, developed an assay system wherein cross-linking 
CTLA-4 with mAbs inhibited T ceils stimulated through 
CD3 and CD28 (10, 11). Finally, recent studies using 
CTLA-4-deficient mice have emphasized the importance of 
the CTLA-4-mediated ownregulatory activity. CTLA-4 
knockout mice demonstrate a massive lymphoproliferative 
response (16, 17). In the present studies, we address the 
mechanism by which CTLA-4 downregulates T cell func- 
tion. The data suggest that CTLA-4 does not mediate its 
effects through Fas-mediated or other forms of pro- 
grammed cell death. However, CTLA-4 cross-linking in- 
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hibits cell cycle progression, sustained IL-2Rot expression 
and IL-2 production. Furthermore, the most profound ef- 
fects of CTLA-4 cross-linking occur in the presence of 
maximal CD28-mediated T cell costimulation. 
There are several possible models for how CTLA-4 may 
be antagonizing CD28-mediated signals. It is possible that 
CTLA-4 may inhibit T cell activation by directly antago- 
nizing initial CD28 signals, especially since CTLA-4 has a 
higher affinity for B7-1 and B7-2 than does CD28 (7, 38). 
This "cell surface competition" hypothesis does not fully 
explain the results for two reasons. First, we have observed 
opposing effects of whole versus Fab fragments of the anti- 
CTLA-4 mAbs. The addition of whole anti-CTLA-4 mAb 
inhibited T cell activation when anti-CD3 and anti-CD28 
were present, while the addition of Fab fragments to the 
culture had no effect or actually enhanced T cell prolifera- 
tion. If CTLA-4 was merely competing with CD28 for in- 
teraction with the B7 family members, both Fab fragments 
and whole anti-CTLA-4 mAbs would be expected to aug- 
ment proliferation by blocking CTLA-4 interactions with 
the counter-receptors, thus making more of the B7-family 
member molecules available for CD28 ligation. Second, if 
CTLA-4 was competing with CD28 for B7 ligation, then 
CD28 signaling would have been expected to be impaired 
on the naive T cells. It has previously been shown that the 
blockade of CD28/B7 interactions leads to a rapid decrease 
in cell survival as a direct result of apoptosis (5). The 
present study showed that inhibition of T cell proliferation 
after CTLA-4 cross-linking was not related to apoptosis, al- 
though we cannot rule out that rapid apoptosis of cells 
might not be detected in these cultures. However, overall 
cell yield over time would not be consistent with this inter- 
pretation of the data. Analyses ofFas-defective T cells failed 
to provide any evidence of increased cell death among T 
cells cultured with the anti-CTLA-4 mAb, nor did the 
mAb affect augmentation of cell survival effected by anti- 
CD28. Gribben et al. (18) have suggested that CTLA-4 
may regulate T cell function by inducing apoptosis of acti- 
vated T cells, since, in their study, one anti-CTLA-4 inAb 
was shown to directly mediate apoptosis of human allore- 
active T cell clones. There are two important differences 
that may explain the differences between our study and 
those of Gribben et al. First, the anti-CTLA-4 mAb de- 
scribed does not react with the same epitope as UC10- 
4F10-11. UC10-4F10-11 inhibits the interaction orB7-1 or 
B7-2 with murine CTLA-4Ig (data not shown). In contrast, 
the anti-human CTLA-4 mAb studied by Gribben et al. 
(18) was selected for its distinct binding to a CTLA-4 
epitope unrelated to B7 binding. In fact, anti-CTLA-4 an- 
tibodies that intereacted with the 137 binding site did not 
induce apoptosis in their system. Second, our studies used 
primary, naive T cells as opposed to T cell clones. Since T 
cell clones are dependent ultimately on IL-2 for survival, it 
is possible that inhibition of IL-2 production by the T cell 
clones led to the observed programmed cell death in the 
Gribben et al. study (18). 
The finding that anti-CTLA-4 mAbs appeared to prefer- 
entially affect IL-2 production early following T cell activa- 
tion is intriguing. Several early T cell activation events uch 
as entry into cell cycle and initial IL-2R upregulation were 
not altered by CTLA-4 cross-linking. However, IL-2 pro- 
duction was inhibited at the 24-h time point. Lucas et al. 
recently reported similar results documenting that IL-2 
production, but not early IL-2R expression, was severely 
impaired in CD28 knockout mice (39). In addition, Sper- 
ling et al., (Sperling, A.I., J.A. Auger, B. Ehst, I.C. Rulif- 
son, C.B. Thompson, and J.A. Bluestone, manuscript sub- 
mitted for pubhcation) have shown that CD28 signals may 
not be required for early T cell activation events, but are 
necessary for T cell survival and sustained proliferative re- 
sponses. In fact, it is striking that the most profound inhibi- 
tion of T cell activation following TCR cross-linking oc- 
curs in the presence of optimal costimulation through 
CD28. These results suggest hat cross-hnking by anti- 
CTLA-4 mAbs selectively inhibits CD28-dependent sig- 
naling events. The data also support recent suggestions that 
IL-2 production is not essential to initiate the transit of T 
cells into the cell cycle, but that the lack of this growth fac- 
tor may impede cell cycle progression, prevent sustained 
IL-2R expression and T cell expansion. 
Thus, it will be important o determine whether the 
negative signals delivered by CTLA-4 cross-linking directly 
antagonize signals through CD28 (such as the activation of 
protein tyrosine kinases) that are essential for IL-2 mRNA 
induction or regulate signals (such as TCR signals) inde- 
pendent of those mediated by CD28. For instance, CTLA-4 
and CD28 may share common signaling pathways and ini- 
tiation of CTLA-4 signaling may antagonize CD28 signal- 
ing events by preventing the interaction of CD28 with 
necessary cytoplasmic signaling molecules, perhaps by alter- 
ing phosphorylation events. As an example, it has been 
shown that both CD28 and CTLA-4 can bind and activate 
PI-3 kinase (40). However, CTLA-4 hgation may regulate 
PI-3 kinase activity. Alternatively, CTLA-4 cross-linking 
may activate biochemical pathways that antagonize signals 
initiated by CD28. CD28 has been shown to regulate IL-2 
at the level of IL-2 gene transcription and mRNA stability 
(41-43). Thus, CTLA-4 signals may regulate IL-2 secretion 
by inhibiting the induction of specific IL-2 transcription 
factors or affect posttranscriptional stability of IL-2 mRNA. 
Finally, it is difficult to determine from the present stud- 
ies how early CTLA-4 acts in blocking T cell activation. 
The present findings suggest hat CTLA-4 downregulates 
naive T cell activation subsequent to CD28 signaling. Un- 
hke CD28, little CTLA-4 is detectable on naive T cells. 
Rather, CTLA-4 is upregulated after T cell activation, 
peaking on the cell surface at 48-72 h. Moreover, CTLA-4 
upregulation is CD28-dependent, asblockade of CD28 li- 
gation inhibits CTLA-4 induction while increased signal- 
ing through CD28 increases CTLA-4 expression on the 
cell surface (data not shown). Thus, CTLA-4 seems hkely 
to function subsequently to initial T cell activation events. 
However, it remains possible that some T cells, perhaps 
memory or recently activated T cells, may express low lev- 
els of CTLA-4 on the cell surface. Under these circum- 
stances CTLA-4 engagement may block the initiation of T 
cell activation. In either case, it has become increasingly 
clear that CTLA-4 serves a role as a major repressor of the 
immune response. Future studies will focus on manipulat- 
ing this downregulatory function to either enhance subop- 
timal immune responses in cancer and infectious disease or 
block activated T cells in transplantation a d autoimmunity. 
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